4. Bibliografia

  1. Fine KD. Diarrhea. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Sleinsenger and Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management. 6th ed. Philadelphia: WB Saunders, 1998:128-152.
  2. Bramble MG, Record CO. Drug-induced gastrointestinal disease. Drugs 1978;15:451-463.
  3. Johnson RA. Adverse reactions in ten years' general practice, computer-analysed. J R Soc Med 1986;79:143-146.
  4. Beaugerie L, Gendre JP. Drug-induced colitis. Med Hyg 1993;51:2153-2155.
  5. Pariente EA. Drug-induced enteropathies. Gastroenterol Clin Biol 1982;6:16-18.
  6. Micromedex Inc. Micromedex Healthcare Series New Integrated Index™ (online document). Available from: www.micromedex.com (accessed 1999 Nov22).
  7. Bartlett JG. Antibiotic-associated diarrhea. Clin Infect Dis 1992;15:573-581.
  8. Weber DJ, Tolkoff-Rubin RH. Amoxicillin and potassium clavulanate: an antiobiotic combination: mechanism of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy and adverse effects. Pharmacotherapy 1984;4:122-136.
  9. Gales MA, Gales BJ. Recognition of severe cefixime-induced diarrhea. Clin Pharm 1993;12:881.
  10. Schwartzberg JE, Maresca RM, Remington JS. Gastrointestinal side effects associated with clindamycin. 1000 consecutive patients. Arch Intern Med 1976;136:876-879.
  11. Bauwens JE, McFarland LV, Melcher MJ, el al. Recurrent Clotridium difficile disease following ciprofloxacin use. Ann Pharmacother 1997;31:1090.
  12. Periti P, Mazzci T, Mini E, et al. Adverse effects of macrolide antibacterials. Drug Saf 1993;9:346-364.
  13. Nord CE, Heimdahl A, Kager L. Antimicrobial induced alterations of the human oropharyngeal and intestinal microflora. Scand J Infect Dis 1986;49 Suppl.:64-72.
  14. McFarland LV. Risk factors for antibiotic-associated diarrhea. Ann Med Interne 1998;149:261-266.
  15. Rolfe RD, Finegold SM. Intestinal beta-lactamase activity in ampicillin-induced Clostridium difficile associated ileocolitis. J Infect Dis 1983;147:227-235.
  16. Tedesco FJ. Ampicillin-associated diarrhea. A prospective study. Am J dig Dis 1975;4:295-297.
  17. Toffler RB, Pingoud EG, Burrel MI. Acute colitis related to penicillin and penicillin derivatives. Lancet 1978:II:707-709.
  18. Thompson JW, Jacobs RF. Adverse effect of newer cephalosporins. Druf Saf 1993;9:132-142.
  19. Moskovitz BL. Clinical adverse effects during ceftriaxone therapy. Am J Med 1984;77 (Suppl C):84-88.
  20. Werth B, Kobler E, Reinhart WH, et al. Clostridium difficile associated diarrhea in cephalosporin administration: experiences of the Swiss adverse drug reactio reporting system 1981-1995. Schweiz Med Wochenschr 1997;89: Suppl.:5-8.
  21. Jaimes EC. Lincocinamides and the incidence of antibiotic-associated colitis. Clin Ther 1991;13:270-280.
  22. Tedesco FJ, Barton RW, Alpers DH. Clindamycin associated colitis. Ann Intern Med 1974;81:429-433.
  23. Cerny A. Side effects and consequences of frequently used antibiotics in clinical practice. Schweiz Med Wochenschr 1996;126:528-534.
  24. Maignan M, Schuhmacher H, Pierfitte C, et al. Pseudomembranous colitis associated with josamycin. Therapie 1994;49:461-462.
  25. Nawaz A, Mohammed I, Ahsan K, et al. Clostridium difficile colitis associated with treatment of Helicobacter pylori infection. Am J Gastroenteral 1998;93:1175-1176-
  26. Rubin MS, Bodenstein LE, Kent KC. Severe clostridium difficile colitis. Dis Colon Rectum 1995;38:350-354.
  27. McKinley M, Toffler RB. Antibiotic associated hemorragic colitis. Dig Dis Sci 1980;25:812-813.
  28. Blanchi A, Pariente A. Acute hemorrhagic colitis after ingestion of amoxicillin. Gastroenterol Clin Biol 1992;16:1012-1014.
  29. Perez-Castrillon JL, Duenas A, Goyeneche MA, et al. Hemorrhagic colitis due to amoxicillin7clavulanate and nasal decongestants? J Clin Gastroenterol 1197;25:701.
  30. Fort E, Sevestre C, Cahiez M, et al. Acute hemorrhagic colitis after oral ingestion of synergistin. Gastroenterol Clin Biol 1993;17:231-232.
  31. Decaux C, Devroede G. Acute colitis related to spiramycin. Lancet 1978;II:993.
  32. David XR, Pierrugues R, Michel H. Acute hemorrhagic colitis related to oral administration of cephalosporin. Gasrtoenterol Clin Biol 1991;15:659.
  33. Beelaiche G, Le Pennec MP, Choudat L, et al. Value of rectosigmoidoscopy with bacteriological culture of colonic biopsies in the diagnosis of post-antibiotic hemarrhagic colitis realted to Klebsielle oxytoca. Gastroenterol Clin Biol 1997;21:764-767.
  34. Benoit R, Danchequin Dorval E, Loulergue J, et al. Post-antibiotic diarrhea: role of Klebsiella oxytoca. Gastroenterol Clin Biol 1992;16:860-864.
  35. Cleau D, humblot S, Jobard JM, et al. Acute right side hemorrhagic colitis with demonstration of Klebsielle oxytoca after treatment with amoxicillin. Presse Med 1994;23:1879-1880.
  36. Danna PL, Urban C, Bellin E, et al. Role of Candida in pathogenesis of antibiotic-associated diarrhea in elderly inpatients. Lancet 1991;337:511-514.
  37. Longstreth GF, Newcomer AD. Drug-induced malabsorption. Mayo Clin Proc 1975;50:284-293.
  38. Dobbins WO, Herrero BA, Mansbach DM. Morphologic alterations associated with neomycin inducedmalabsorption. Am J Med Sci 1968;80:907-913.
  39. Giannella RA, Serumaga J, Walls D, et al. Effect of clindamycin on intestinal water and glucose transport in the rat. Gastroenterology 1981;80:907-913.
  40. Weber FH, Richards RD, McCallum RW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 1993;88:485-490.
  41. Lees GM, Percy WH. Antibiotic associated colitis: an in vitro investigation of the effects of antibiotics on intestinal motiliy. Br J Pharmacol 1981;73:535-547.
  42. Bjarnason J, MacPherson A. The changing gastrointestinal side effect profile of non steroidal anti-inflammatory drugs. A new approach for the prevention of a new problem. Scand J Gastroenterol 1989;24:56-64.
  43. Davies NM, Can PD. Toxicity of nonsteroidal anti-imflammatory drugs in the large intestine. Dis Colon Rectum 1995;38:1311-1321.
  44. Morgan GJ, Poland M, DeLapp RE. Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly. Am J Med 1993;95 Suppl 2A:19-27.
  45. Lapoile E, Bellaiche G, Notus A, et al. Pseudomembranous colitis after ingestion of diclofenac. Gastroenteral Clin Biol 1998;22:100-101.
  46. Hall RI, Petty AH, Cobden I, et al. Enteritis and colitis associated with mefenamic acid. BMJ 1983;287:1182.
  47. Gibson GR, Withcare EB, Ricotti CA. Colitis induced by nonsteroidal anti-inflammatory drugs. Arch Intern Med 1992;152:625-632.
  48. Kwo PY, Tremaine WJ. Nonsteroidal anti-inflammatory drug-induced enteropathy: case discussion and review of the literature. Mayo Clin Proc 1995;70:55-61.
  49. Bjarnason I, prouse P, Smith T, et al. Blood and protein loss via small-intestinal inflammatory induced by non.steroidal anti-inflammatory drugs. Lancet 1987;II:711-714.
  50. Dao T, Grimaux-Jardin I, Fellous F, et al. Ulcerative colitis secondary to the ingestion of lysine acetysalicylate. Gastroenterol Clin Biol 1993;17:66-67.
  51. Sturges HF, Krone CL. Ulceration and stricture of the jeiunum in a patient on long-term indomethacin therapy. Am J Gastroenterol 1973;59:162-169.
  52. Langmann MJS, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. BMJ 1985:290:347-349.
  53. Bjarnason I, MacPherson AJS. Intestinal toxicity of non-steroidal anti-inflammatory drugs. Pharmacol Ther 1994;62:145-157.
  54. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987;107:513-516.
  55. Wilson RG, Smith AN, McIntyre IMC. Complications of diverticular disease and non-steroidal anti-inflammatory drugs: a prospective study. Br J Surg 1990;77:1103-1104.
  56. Fang WF, Broughton A, Jacobson ED. Indomethacin-induced intestinal inflammation. Am J Dig Dis 1997;22:749-760.
  57. Rutherford D, Stockdill G, Hamer-Hodges DW, et al. Proctocolitis induced by salicilate. BMJ 1984;288:794.
  58. Chakraborty TK, Bhatia D, Heading RC, et al. Salicylate induced exacerbation of ulcerative colitis. Gut 1987;28:613-615.
  59. Barnejee AK. Enteropathy induced by non-steroidal anti-inflammatory drugs often subclinical but may mimic Crohn's disease. BMJ 1989;298:1539-1540.
  60. Ridell RH, Tanaka M, Mazzoleni G. Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: a case-control study. Gut 1992;33:683-686.
  61. Giardiello FM, Hansen FC, Lazenby AJ, et al. Collagenous colitis setting of non steroidal antiinflammatory drugs and antibiotics. Dig Dis Sci 1990;35:257-260.
  62. Bridges AJ, Marshall JB, Diaz-Arias AA, et al. Acute eosinophilic colitis and hypersensitivity reaction associated with naproxen therapy. Am J Med 1990;89:526-527.
  63. Horvath F, Marbury TC, Uhlemann ER, et al. Severe diarrhea secondary to propranolol. South Med 1979;72:367-368.
  64. Robinson JD, Burtner DE. Severe diarrhea secondary to propranoll. Drug Intell Clin Pharm 1981;15:49-50.
  65. Rolachon A, Bichard P, Kezachian G, et al. Chronic diarrhea caused by isradipine. Gastroenterol Clin Biol 1993;17:310-311.
  66. Hedner T. Calcium channel blockers: spectrum of side effects and drug interactions. Acta Pharmacol Toxicol 1986;58:Suppl.2:119-130.
  67. Quart BD, Guglielmo BJ. Prolonged diarrhea secondary to methyldopa therapy. Drug Intell Clin Pharm 1983;17:642.
  68. Gloth FM, Busby MJ. Methyldopa-induced diarrhea: case of iatrogenic diarrhea leading to request for nursing home replacement. Am J Med 1989;87:480-481.
  69. Graham CF, Gallagher K, Jones JK. Acute colitis with methyldopa . N Engl J Med 1981;304:1044-1045.
  70. Mahdyoon H, Battilana G, Rosman H, et al. The evolving patern of digoxin intoxication: observation at a large urban hospital from 1980-1988. Am Heart J 1990;120:1189-1194.
  71. Andrews PA, Wilkinson PR. Diarrhea as a side effect of digoxin. BMJ 1990;301:1398.
  72. Bourhis T, Riard P, Danel V, et al. Digitalis poisoning with severe ischemic colitis: a favorable course after treatment with specific antibodies. Gastroenterol Clin Biol 1990;14:95.
  73. Cohen IS, Jick H, Cohen SI, et al. Adverse reactions to quinidine in hospitalized patients: findings based on data from Boston Collaborative Drug Survellaince Program. Prog Cardiovasc Dis 1977;20:152-163.
  74. Auricchio RJ. Cardiac arrhythmias. In: Young LY, Koda-Kimble MA, editors. Applied therapeutics: the clinical use of drugs, 4th ed. Vancouver: Applied Therapeutics, 1988.
  75. Romakiewicz JA, Reidenberg M, Drayer D, et al. The noninterference of aluminium hydroxide gel with quinidine-induced diarrhea. Am Heart J 1978;96:518-520.
  76. Rudusky BM. Cholestyramine therapy for quinidine-nduced diarrhea. Case reports. Angiology 1997;48:173-176.
  77. Guedon C, Bruna T, Ducrottè P, et al. Severe diarrhea caused by Ticlid associated with disorders of small intestine motility. Gastroenterol Clin Biol 1989;13:934-937.
  78. Giardina MG, Matarazzo M, cacciatoerL, et al. Ticlpidine can cause chronic diarrhea. Lancet 1989;13:934-937.
  79. Chassany O, Bacq Y, metman EH, et al. Severe chronic diarrhea during treatment with ticlopidine. Gastroenterol Clin Biol 1989;13:950.
  80. Fraga Md, garcia B, Agud JL, et al. Severe chronic diarrhea by riclopidine. Ann Pharmacother 1996;30:1496.
  81. Mansoor GA, Aziz K. Delayed chronic diarrhea and wieght loss possibly due to ticlopidine therapy. Ann Pharmacother 1997;31:870-872.
  82. Berrebi D Sautet A, Flejou JF, et al. Ticlopidine induced cilitis: a histopathological study including apoptosis. J Clin Pathol 1998;51:280-283.
  83. Bouaniche M, Chassage P, Landrin I, et al. Lymphocytic colitis caused by Cyclo 3 Fort. Rev Med Int 1996;17:776-778.
  84. Thomas-Anterion C, guy.C, Vial F, et al. Unexplained chronic diarrhea. A propos of 4 new cases Cyclo 3 Fort and review of the literature. Rew med Interne 1993;14:215-217.
  85. Maechel H. Cikan-induced chronic diarrhea. Gastroenterol Clin Biol 1992;16:373.
  86. Raoul JL, Dautreme S, Heresbach N, et al. Chronic diarrhea secondary to Veinotonyl 75. Ann gastroenterol Hepatol 1994;30:25.
  87. Hastier P, Bianchi D, Chichmanian RM, et al. Chronic diarrhea secondary to Veinamitol. Therapie 1994;49:149-149.
  88. Furst DE. Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritis. Pharmacotherapy 1983;3:284-298.
  89. Wallin BA, McCafferty JP, et al. Incidence and managemnet of diarrhea during long term auranofin therapy. J Rheumatol 1988;15:1755-1758.
  90. Jackson CW, Haboubi NY, Whorwell PJ, et al. Gold induced enterocolitis. Gut 1986;27:452-456.
  91. Marcuard SP, Ehrinpreis MN, Fitter WF. Gold induced ulcerative proctitis: report and review of the literature. J Rheumatol 1987;14:142-144.
  92. Bross-Bach U, Saal JG, Hartmann F, et al. Ulcerative colitis caused by oral gold therapy in rheumatoid arthritis. Z Rheumatol 1987;46:201-204.
  93. Luzzani M, Vidili MG, Rissotto R, et al. Disodium clodronate in the treatment of pain due to bone metastases. Int J Clin Pharm Res 1990;10:243-246.
  94. Khairi MR, Altman RD, deRosa GP, et al. Sodium etidronate in the treatment of Paget's disease of bone. A study of long term results. Ann Intern Med 1977;87:656-663.
  95. Verne GN, Eaker EY, Davis RH, et al . Colchicine is an effective treatment for patients with chronic constipation: an openlabel trial. Dig Dis Sci 1997;42:1959-1963.
  96. Ehrenfeld M, Levy M, Sharon P, et al. Gastrointestinal effects of long-term colchicine therapy in patients with recurrent polyserositis (familial Mediterranean fever). Dig Dis Sci 1982;27:723-727.
  97. Nguyen M, Dougados M, Berdah L, et al. Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum 1994;37:529-536.
  98. Blondon H, Bikart I, Bergmann JF. Severe diarrhea with hypokalemia attributed to diacetylrhein. Gastroenterol Clin Biol 1995;19:851-852.
  99. Pitt P, berry H. Fluoride tretment in osteoporosis. Postgrad Med J 1991;67:323-326.
  100. Pak CY, Sakhaee K, Gallagher C, et al. Attainment of therapeutic fluoride levels in serum without major side effects using a slow-release preparation of sodium fluoride in postmenopausal osteoporosis. J Bone Miner Res 1986;1:563-567.
  101. Zorzin L, capone M. Postmenopausalosteoporosis: therapeutic and side effects of different calcitonins. Curr Ther Res 1984;36:473-482.
  102. McGuinness ME, Talbert RL. Phenformin-induced lactc acidosis: a forgotten adverse drug reaction. Ann Pharmacother 1993;27:1183-1187.
  103. Federlin KF, Mehlburger L, Hillebrand I, et al. The effect of two new glucosidase inhibitors on blood glucose in healhy volunteers and type 2 diabetics. Acta Diabetol Lat 1987;27:213-221.
  104. Hollander P. Safety profile of acarbose, an alpha-glucosidase inhibitor. Drugs 1992;44 Suppl.2:47-53
  105. Johnston PS, Feigu PU, Coniff RF, et al. Long-term titrated-dose alpha-glucosidase inhibitor in non-insulin-requiring Hispanic NIDDM patients. Diabetes Care 1998;21:409-415.
  106. Chawla A, Karl PI, Reich RN, et al. Effect of olsalazine on sodium-dependent bile acid transport in rat ileum. Dig Dis Sci 1995;40:943-948.
  107. Pamukcu R, Hanauer SB, Chang EB. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfalazine and 5-aminosalicylic acid. Gastroenterology 1988;95:975-981.
  108. Wright JP, O'Keefe EA, Cuming L, et al. Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Dig Dis Sci 1993;38:1837-1842.
  109. Travis SP, Tysk C, de Silva HJ, et al. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 1994;35:1282-1286.
  110. Raimundo AH, Patil DH, Frost PG, et al. Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects. Gut 1991;32:270-274.
  111. Van Gaal LF, Broom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharmacol 1998;54:125-135.
  112. Sjostrom L, Rissanem A, Andersen T, et al. Randomised placebo-controlled trials of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;56:241-249.
  113. McNeely W, Benfield P. Orlistat. Drugs 1998;56:241-249.
  114. Bow EJ, Gallant GJ, Woloschuk D, et al. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin. Cancer 1998;83:1344-1349.
  115. Jarvis B, Shevchuk YM. Recurrent Clostridium difficile diarrhea associated with mitoxantrone and etoposide: a case report and review. Pharmacotherapy 1997;17:606-611.
  116. Anand A, Glatt AE. Clostridium Difficile infection associated with antineoplastic chemoterapy: a review. Clin Infect Dis 1993;17;109-113.
  117. Husain A, Aptaker L, Spriggs DR, et al. Gastrointestinal toxicity and Clostridium Difficile diarrhea in patients trwated with paclitaxel-containig chemoterapy regimens. Gynecol Oncol 1998;71:104-107.
  118. Cudmore MA, Silva J, Fekety R et al. Clostridium difficile colitis associated with cancer chemotherapy. Arch Intern Med 1982;142:333-335.
  119. Jackson IM, Barnard LB, Lamberton P. Role of a long-acting somatostatin analogue (SMS 201-995) in the treatmnet of acromegaly. Am J Med 1986;81:94-101.
  120. HoPJ, Boyaji LD, Greenstein E, et al. Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly. Dig Dis Sci 1993;38:308-315.
  121. Nakamura T, Kudoh K, Takebe K, et al. Octreotide decreases biliary and pancreatic exocrine function, and induces steatorrhea in healthy subjects. Intern Med 1994;33:593-596.
  122. Kuhn JM, Legrand A, Ruiz JM, et al. Pharmacokinetic and pharmacodynamic properties of a long-actinf formulation of the new somatostatin analogue, lanreotide, n normal healthy volunteers. Br J Clin Pharmacol 1994;38:213-219.
  123. Maton PN, Iser JH, Reuben A, et al. Outcome of chenodeoxycholic acid (CDCA) treatment in 125 patients with radiolucent gallstones. Medicine 1982;61:86-97.
  124. Kruis W, Haddad A, Phillips SF. Chenodeoxycholic and ursodeoxycholic acid alter motility anf fluid transit in the canine ileum. Digestion 1986;34:185-195.
  125. Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol 1987;2:10-32.
  126. Sackmann M, Paulezki J, Aydemir U, et al. Efficacy anf safety of ursodeoxycholic acidfor dissolution of gallstone fragments: comparison with the combination of ursodeoxycholic acid and chenodeoxycholic acid. Hepatology 1991;14:1136-1141.
  127. Piper DW. A comparative overiew of the adverse effects of antiulcer drugs. Drug Saf 1995;12:120-138.
  128. Yen L. Cimetidine-induced diarrhea. Drug Intell Clin Pharm 1985;19:185.
  129. Beaugerie L, patey N, Brousse N. Ranitidine, diarrhea, and lymphocytic colitis. Gut 1995;37:708-711.
  130. Beaugerie L, Berrebi D, Dikov D, et al. Epithelial apoptosis a very early marker of drug-induced colitis. The example of ranitidine. Gastroenterol Clin Biol 1996;20:918-920.
  131. Duncan HD, Talbot IC, Silk DB. Collagenous colitis and cimetidine. Eur J Gastroenterol Hepatol 1997;9:819-820.
  132. Field R, Meyers GW. Diarrhea From cimetidine. N Engl J Med 1978;299:262.
  133. Leufkens H, Claessens A, Heerdink E, et al. A prospective follow-up study of 5669 users of lansoprazole in daily practice. Aliment Pharmacol Ther 1997;11:887-897.
  134. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995;123:241-249.
  135. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993;119:257-262.
  136. Bocanegra TS, Weaver AL, Tindall EA, et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled tral. Arthrotec osteoarrthritis study group. J Rheumatol 1998;25:1602-1611.
  137. Gagnier P. Review of the safety of diclofenac/misoprostol. Drugs 1993;45 Suppl.:31-35.
  138. Davis R, Yarker YE, Goa KL. Diclofenac/misoprostol: a review of its pharmacology and therapeutic efficacy in painful inflammatory conditions. Drugs Aging 1995;7:372-393.
  139. Melo Gomes JA, Roth SH, Zeeh J, et al. Double-blind comparison of efficacy and gastroduodenal safety od diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993;52:881-885.
  140. Castell DO, Sigmund C, Patterson D, et al. Cisapridw 20mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 investigator group. Am J Gastroenterol 1998;93:547-552.
  141. Wiseman LR, Faulds D. Cisapride . An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994;47:116-152.
  142. Labayle D, Delas N, Pariente A, et al. Severe psychiatric disorders associated with severe acute colitis. Gastroenterol Clin Biol 1992;16:639-643.
  143. Basse P. Ischemic colitis complicating imipramine overdose and alcohol ingestion. Eur J Surg 1992;158:187-188.
  144. Meya U, Moller B, Renfordt E, et al. A case of perazine-induced enteritis. Allergy or pseudoallergy? Pharmacopsychiatry 1985;18:263-266.
  145. Anttila VJ, Valtonen M. Carbamazepine-induced eosinophilic colitis. Epilepsia 1992;33:119-121.
  146. Gracon SI, Knapp MJ, Berghoff WG, et al. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis Assoc Disord 1998;12:93-101.
  147. Rogers SL, Doody RS, mohs RC, et al. Donezepil improves cognition and global function in Alzheimer disease: a 15 week, double-blind, placebo-controlled sudy. Donezepil study group. Arch Intern Med 1998;158:1021-1031.
  148. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997;17:208-221.
  149. Bever KA, Perry PJ. Dexfenfluramine Hydrochloride: an anorexigenic agent. Am J Health Syst Pharm 1997;54:2059-2072.
  150. Wagner ML, Landis BE. Riluzole: a new agent for amyotrophic lateral sclerosis. Ann Pharrmacother 1997;31:738-744.
  151. Murphy EA, Morris AJ, Walker E, et al. Cyclosporine A induced colitis and acquired selective IgA deficiency in a patient with juvenile chronic arthritis. J Rheumatol 1993;20:1397-1398.
  152. Bowen JR, Sahi S. Cyclosporin induced colitis BMJ 1993;307:484.
    153.
Precedente
Indice